Holistic Healing for Knee Osteoarthritis (HEAL-KOA)
Holistic Healing for Knee Osteoarthritis: Comparing Integrated, Standard Medical, and Ayurvedic Care
This study is a single-center, three-arm, open-label randomized controlled trial designed to compare the effectiveness of integrated care, standard medical care, and Ayurvedic care in adults with early knee osteoarthritis (Kellgren-Lawrence grades I-II). Knee osteoarthritis is a leading cause of pain, functional limitation, and reduced quality of life, and current management often provides incomplete symptom relief. Although conventional medical and Ayurvedic interventions are widely used in clinical practice, comparative evidence evaluating these treatment approaches individually and in combination remains limited.
A total of 300 participants aged 30-65 years with primary knee osteoarthritis will be randomly allocated in a 1:1:1 ratio to receive standard medical care, Ayurvedic care, or integrated care. The standard medical care group will receive oral paracetamol, topical diclofenac spray, transcutaneous electrical nerve stimulation (TENS), and superficial heat or cold therapy. The Ayurvedic care group will receive Trayodashang Guggulu, Ashwagandha Churna, Janubasti therapy, and topical application of Mahanarayana Taila. The integrated care group will receive Trayodashang Guggulu, Ashwagandha Churna, topical diclofenac spray, and portable transcutaneous electrical nerve stimulation (TENS). Participants will be followed for 24 weeks.
Primary outcome measures include changes in knee pain intensity, knee osteoarthritis symptoms, knee joint surface temperature, and gait kinematic parameters. Secondary outcome measures include changes in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). The findings of this study are expected to provide evidence regarding the comparative effectiveness of integrated care, standard medical care, and Ayurvedic care in the management of early knee osteoarthritis.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Knee osteoarthritis (KOA) is one of the most prevalent chronic musculoskeletal disorders and a leading cause of pain, disability, reduced mobility, and impaired quality of life worldwide. Conventional medical management primarily focuses on reducing pain and improving function through pharmacological and non-pharmacological interventions, whereas Ayurvedic management utilizes a holistic approach incorporating herbal medications and external therapeutic procedures. Although both treatment approaches are widely practiced, comparative evidence evaluating conventional medical care, Ayurvedic care, and an integrated treatment approach remains limited. This study aims to compare the effectiveness of these three treatment strategies in individuals with early knee osteoarthritis.
This study is a single-center, three-arm, open-label randomized controlled trial in which 300 participants aged 30-65 years with primary knee osteoarthritis (Kellgren-Lawrence grades I-II) will be randomly allocated in a 1:1:1 ratio to receive standard medical care, Ayurvedic care, or integrated care. Participants will be followed for 24 weeks after randomization. Baseline assessments will include demographic characteristics, clinical examination, radiographic evaluation, and laboratory investigations.
Participants allocated to the Standard Medical Care group will receive oral paracetamol, topical diclofenac spray, transcutaneous electrical nerve stimulation (TENS), and superficial heat or cold therapy.
Participants allocated to the Ayurvedic Care group will receive Trayodashang Guggulu, Ashwagandha Churna, Janubasti therapy, and topical application of Mahanarayana Taila.
Participants allocated to the Integrated Care group will receive Trayodashang Guggulu, Ashwagandha Churna, topical diclofenac spray, and portable transcutaneous electrical nerve stimulation (TENS).
The primary objective of the study is to compare the effectiveness of the three treatment approaches in reducing knee pain, improving knee osteoarthritis symptoms, reducing joint inflammation, and improving gait. Primary outcome measures include changes in knee pain intensity assessed using the Visual Analogue Scale (VAS), knee osteoarthritis symptoms assessed using the CRD Pune version of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), knee joint surface temperature assessed using infrared thermography, and gait kinematic parameters assessed using three-dimensional gait analysis. Outcome assessments will be performed at baseline and during follow-up according to the study schedule.
Secondary outcome measures include changes in erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) to evaluate systemic inflammation associated with the three treatment approaches.
The findings of this study are expected to provide evidence regarding the comparative effectiveness of integrated care, standard medical care, and Ayurvedic care in improving pain, physical function, joint inflammation, gait, and quality of life among individuals with early knee osteoarthritis. The results may contribute to the development of evidence-based integrative treatment strategies for the management of early knee osteoarthritis.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Nitesh M Gonnade, MBBS, MD(PMR)
- 電話番号:91 9530199967
- メール:drniteshgonnade9@gmail.com
研究連絡先のバックアップ
- 名前:Shobhan B Varthya, MBBS, MD(Pharmacology)
- 電話番号:91 8437726777
- メール:drshobanpgimer@gmail.com
研究場所
-
-
Rajasthan
-
Jodhpur、Rajasthan、インド、342005
- All India Institute of Medical Sciences, Jodhpur
-
コンタクト:
- Nitesh M Gonnade, MBBS, MD(PMR)
- 電話番号:91 9530199967
- メール:drniteshgonnade9@gmail.com
-
コンタクト:
- Shobhan B Varthya, MBBS, MD(Pharmacology)
- 電話番号:91 8437726777
- メール:drshobanpgimer@gmail.com
-
主任研究者:
- Nitesh M Gonnade, MBBS, MD(PMR)
-
副調査官:
- Meenakshi Sharma, BAMS, MD(Ayurveda)
-
副調査官:
- Purvi Purohit, PhD (medical) Biochemistry
-
副調査官:
- Kamla K Shukla, Ph.D(Med Biochemistry) Postdoc
-
副調査官:
- Om Lata Bhagat, MBBS, MPH, MD (Physiology)
-
副調査官:
- Ravi Gaur, MBBS, MD(PMR), DNB(PMR), PGDHM
-
副調査官:
- GyanPrakash Sharma, BAMS, MD (Ayurveda)
-
副調査官:
- Purnandu Sharma, BAMS, MD (Yoga & Rehab)
-
副調査官:
- Sandeep K Yadav, MBBS, MS (Orthopedics)
-
副調査官:
- Prem P Sharma, PhD and MSc (Statistics), PSCC
-
副調査官:
- Nitesh Gahlot, MS and DNB Ortho, MANMS, FACS
-
副調査官:
- Shobhan B Varthya, MBBS, MD(Pharmacology)
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age between 30 and 65 years, including males and females both
- Diagnosis of primary osteoarthritis (OA) affecting at least one knee joint.
- Kellgren-Lawrence (KL) grading of 1 or 2, indicating mild to moderate OA severity.
- Baseline Numeric Rating Scale (NRS) score of ≥ 5 out of 10, indicating moderate to severe pain intensity.
Exclusion Criteria:
- Secondary arthritis due to systemic inflammatory arthritis.
- History of post-traumatic knee osteoarthritis.
- Previous total knee replacement (TKR) surgery.
- Recent corticosteroid use for knee-related conditions.
- Prior intra-articular viscosupplementation treatment.
- Allergy to allopathic and Ayurvedic medications used in the study.
- Concomitant skin disease at the application site of any study intervention.
- Uncontrolled diabetes mellitus
- Chronic Renal failure
- Pregnant and lactating females
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
アクティブコンパレータ:Standard Medical Care
Participants assigned to this arm will receive standard medical management for knee osteoarthritis for 24 weeks. Treatment includes oral paracetamol, topical diclofenac spray administered as required for pain relief, transcutaneous electrical nerve stimulation (TENS), and superficial heat or cold therapy. Participants will be assessed at baseline and followed at 4, 8, 12, 16, 20, and 24 weeks. |
Topical diclofenac spray is a non-steroidal anti-inflammatory drug (NSAID) formulation applied locally over the affected knee as required for symptomatic pain relief during the 24-week intervention period. Portable transcutaneous electrical nerve stimulation (TENS) is a non-invasive electrotherapy device that delivers low-voltage electrical stimulation through surface electrodes placed around the affected knee for pain management during the 24-week intervention period. Paracetamol is a non-opioid analgesic administered orally for symptomatic pain relief during the 24-week intervention period in the Standard Medical Care group and permitted as rescue (SOS) medication for symptomatic pain relief when clinically required in the Ayurvedic Care and Integrated Care groups. Superficial heat or cold will be applied locally to the affected knee as a non-pharmacological intervention for symptomatic management of knee osteoarthritis during the 24-week intervention period. |
|
実験的:Ayurvedic Care
Participants assigned to this arm will receive oral Trayodashang Guggulu (1 g twice daily with lukewarm water), Ashwagandha Churna (3 g twice daily with lukewarm water), Janubasti administered according to the predefined schedule, and topical application of Mahanarayana Taila (10 mL per knee; total 20 mL per application) applied twice daily for 24 weeks. Janubasti will be administered in 21 sessions, with 7 sessions during Weeks 1-2, 7 sessions during Weeks 9-10, and 7 sessions during Weeks 17-18. Participants will undergo scheduled follow-up assessments throughout the study. |
Trayodashang Guggulu is an Ayurvedic polyherbal formulation administered orally as tablets at a dose of 1 g twice daily with lukewarm water for 24 weeks for the management of knee osteoarthritis. Ashwagandha Churna is an Ayurvedic herbal powder derived from the root of Withania somnifera and administered orally at a dose of 3 g twice daily with lukewarm water for 24 weeks. Janubasti is an Ayurvedic external therapeutic procedure in which warm Mahanarayana Taila is retained over the affected knee within a dough ring for 30-35 minutes. A total of 21 sessions will be administered, with 7 sessions during Weeks 1-2, 7 sessions during Weeks 9-10, and 7 sessions during Weeks 17-18. Mahanarayana Taila is an Ayurvedic medicated oil applied topically over both knees at a dose of 10 mL per knee (20 mL per application) twice daily for 24 weeks. |
|
実験的:Integrated Care
Participants assigned to this arm will receive oral Trayodashang Guggulu (1 g twice daily), Ashwagandha Churna (3 g twice daily), topical diclofenac spray as required, and portable transcutaneous electrical nerve stimulation (TENS) for 24 weeks. Participants will undergo scheduled follow-up assessments at Weeks 4, 8, 12, 16, 20, and 24. |
Topical diclofenac spray is a non-steroidal anti-inflammatory drug (NSAID) formulation applied locally over the affected knee as required for symptomatic pain relief during the 24-week intervention period. Portable transcutaneous electrical nerve stimulation (TENS) is a non-invasive electrotherapy device that delivers low-voltage electrical stimulation through surface electrodes placed around the affected knee for pain management during the 24-week intervention period. Superficial heat or cold will be applied locally to the affected knee as a non-pharmacological intervention for symptomatic management of knee osteoarthritis during the 24-week intervention period. Trayodashang Guggulu is an Ayurvedic polyherbal formulation administered orally as tablets at a dose of 1 g twice daily with lukewarm water for 24 weeks for the management of knee osteoarthritis. Ashwagandha Churna is an Ayurvedic herbal powder derived from the root of Withania somnifera and administered orally at a dose of 3 g twice daily with lukewarm water for 24 weeks. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Knee Pain Intensity Assessed by the Visual Analogue Scale (VAS)
時間枠:Baseline, Weeks: 4, 8, 12, 16, 20 and 24
|
Knee pain intensity will be assessed using the Visual Analogue Scale, a 10-cm scale ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity and represent a worse outcome, whereas lower scores indicate less pain intensity and represent a better outcome. The primary outcome measure is the change in Visual Analogue Scale score from baseline to each scheduled assessment during the 24-week intervention period. |
Baseline, Weeks: 4, 8, 12, 16, 20 and 24
|
|
Change in Physical Function, Pain, and Stiffness Assessed by the CRD Pune Version of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
時間枠:Baseline, Weeks: 4, 8, 12, 16, 20, and 24
|
Physical function, pain and stiffness will be assessed using the validated CRD Pune Version of the Western Ontario and McMaster Universities Osteoarthritis Index. The scale consists of 24 items, each scored from 0 to 4, with a total score ranging from 0 to 96. The Pain domain ranges from 0 to 20, the Stiffness domain from 0 to 8 and the Physical Function domain from 0 to 68. Higher scores indicate greater pain, stiffness and physical functional difficulty and represent a worse outcome, whereas lower scores indicate less pain, stiffness and physical functional difficulty and represent a better outcome. The primary outcome measure is the change in Western Ontario and McMaster Universities Osteoarthritis Index total and domain scores from baseline to each scheduled assessment during the 24-week intervention period. |
Baseline, Weeks: 4, 8, 12, 16, 20, and 24
|
|
Change in Knee Joint Inflammation Assessed by Infrared Thermography
時間枠:Baseline, Weeks: 4, 8, 12, 16, 20, and 24
|
Knee joint inflammation will be assessed using infrared thermography by measuring changes in skin surface temperature over the affected knee. The primary outcome measure is the change in thermographic findings from baseline to each scheduled assessment during the 24-week intervention period. |
Baseline, Weeks: 4, 8, 12, 16, 20, and 24
|
|
Change in Gait Kinematics Assessed Using G-Walk
時間枠:Baseline, Week 12, and Week 24
|
Gait kinematics will be assessed using the G-Walk system to evaluate changes in gait patterns and mobility. The outcome measure is the change in gait kinematic parameters from baseline to Week 12 and Week 24. |
Baseline, Week 12, and Week 24
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Erythrocyte Sedimentation Rate (ESR)
時間枠:Baseline and Week 24
|
Systemic inflammation will be assessed by measuring erythrocyte sedimentation rate (ESR). The outcome measure will be the change in ESR values from baseline. |
Baseline and Week 24
|
|
Change in Serum C-Reactive Protein (CRP)
時間枠:Baseline and Week 24
|
Systemic inflammation will be assessed by measuring serum C-reactive protein (CRP). The outcome measure will be the change in CRP concentration from baseline. |
Baseline and Week 24
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Nitesh M Gonnade, MBBS, MD(PMR)、All India Institute of Medical Sciences, Jodhpur
出版物と役立つリンク
一般刊行物
- Bookman AA, Williams KS, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ. 2004 Aug 17;171(4):333-8. doi: 10.1503/cmaj.1031793.
- Hanada M, Takahashi M, Furuhashi H, Koyama H, Matsuyama Y. Elevated erythrocyte sedimentation rate and high-sensitivity C-reactive protein in osteoarthritis of the knee: relationship with clinical findings and radiographic severity. Ann Clin Biochem. 2016 Sep;53(Pt 5):548-53. doi: 10.1177/0004563215610142. Epub 2015 Sep 17.
- Wu Y, Zhu F, Chen W, Zhang M. Effects of transcutaneous electrical nerve stimulation (TENS) in people with knee osteoarthritis: A systematic review and meta-analysis. Clin Rehabil. 2022 Apr;36(4):472-485. doi: 10.1177/02692155211065636. Epub 2021 Dec 31.
- Boekesteijn RJ, van Gerven J, Geurts ACH, Smulders K. Objective gait assessment in individuals with knee osteoarthritis using inertial sensors: A systematic review and meta-analysis. Gait Posture. 2022 Oct;98:109-120. doi: 10.1016/j.gaitpost.2022.09.002. Epub 2022 Sep 6.
- De Marziani L, Boffa A, Angelelli L, Andriolo L, Di Martino A, Zaffagnini S, Filardo G. Infrared Thermography in Symptomatic Knee Osteoarthritis: Joint Temperature Differs Based on Patient and Pain Characteristics. J Clin Med. 2023 Mar 16;12(6):2319. doi: 10.3390/jcm12062319.
- Chopra A, Lavin P, Patwardhan B, Chitre D. A 32-week randomized, placebo-controlled clinical evaluation of RA-11, an Ayurvedic drug, on osteoarthritis of the knees. J Clin Rheumatol. 2004 Oct;10(5):236-45. doi: 10.1097/01.rhu.0000138087.47382.6d.
- Modak MD, Barde MP. Efficacy of an Ayurvedic Formulation for Mild-to-moderate Osteoarthritis: A Phase 3, Randomized Controlled Study. Altern Ther Health Med. 2017 Jan;23(1):26-33.
- Kessler CS, Dhiman KS, Kumar A, Ostermann T, Gupta S, Morandi A, Mittwede M, Stapelfeldt E, Spoo M, Icke K, Michalsen A, Witt CM. Effectiveness of an Ayurveda treatment approach in knee osteoarthritis - a randomized controlled trial. Osteoarthritis Cartilage. 2018 May;26(5):620-630. doi: 10.1016/j.joca.2018.01.022. Epub 2018 Feb 7.
- Ariana M, Afrasiabifar A, Najafi Doulatabad S, Mosavi A, Behnammoghadam M. The Effect of Local Heat Therapy versus Cold Rub Gel on Pain and Joint Functions in Patients with Knee Osteoarthritis. Clin Nurs Res. 2022 Jul;31(6):1014-1022. doi: 10.1177/10547738211035502. Epub 2021 Jul 26.
- Yaligod V, Raj DG, Sharma AB, Swami B M, Batra S, Acharya A, Maroo SH, Patel KR, Prajapati V. Dual release paracetamol in osteoarthritis of knee: a randomized controlled clinical trial. J Clin Diagn Res. 2014 Nov;8(11):LC11-5. doi: 10.7860/JCDR/2014/10052.5197. Epub 2014 Nov 20.
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- AIIMS/IEC/2025/5532
- EMDR/CAR/12/2023-00413 (その他の助成金/資金番号:Indian Council of Medical Research (ICMR))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。